Calcimimetics in the pharmacotherapy of secondary hyperparathyroidism - the choice between peroral and parenteral dosage form
Abstract
Secondary hyperparathyroidism in patients with chronic kidney disease and namely with kidney failure represents a severe problem with systemic consequences. This disorder needs appropriate treatment.
Pharmacological approach is represented by vitamin D receptor activators (namely by paricalcitol) and calcium sensing receptor activators, i.e. calcimimetics. Both these pharmacological ways act complementary.
Calcimimetics are available in two pharmagological forms - peroral (cinacalcet) and parenteral (etelcalcetide). Both these drugs reveal certain common effects, but they also have some differences.
These differences are linked not only to their different pharmacokinetics and pharmacodynamics profiles, but also to the different potential to drug-drug interaction. Both calcimimetics effectively lower PTH, but this effect is more expressed by etelcalcetide.
Detailed data are described in this article. For clinical practice, the possibility of choice the given calcimimetic drug according the individual patient s characteristics remains essential.